The global landscape of drug development is changing rapidly.

In this episode of the Good Medicine Podcast, Dr. David Bearss and Dr. Jeremiah Bearss discuss the rise of China as a major force in biotech and pharmaceutical innovation.

Over the past several years, China has moved from a relatively small player to one of the most active regions for drug development and major deal-making. By changing how drugs are developed, including speed, cost, and efficiency, Chinese companies are increasingly competing on a global scale.

They explore what this shift means for U.S. biotech companies, the challenges of competing in a faster and more cost-effective system, and how global partnerships are evolving as a result.

The conversation also touches on the pressure facing large pharmaceutical companies, including upcoming patent expirations and the need to replace significant revenue, which may further accelerate global collaboration.

Topics covered include:

• The shift in biotech deal-making toward China• Competitive pressures facing U.S. companies• The impact of patent expirations on global strategy

🎧 Listen on Spotify and Apple Podcasts📺 Subscribe for more conversations on science, medicine, and innovation.

Thank you to our sponsorsBioHive: https://www.biohive.comGalvan: https://galvan.sng.link/D4mh8/oe8k/litt

Follow Good Medicine PodcastInsta: https://www.instagram.com/good.medicine.podcast/X: https://x.com/GoodMedicinePodTikTok: https://www.tiktok.com/@good.medicine.podcastLinkedIn: https://www.linkedin.com/company/goodmedicinepodcast/